ALXO: ALX Oncology Net earnings per share (EPS TTM)

The 12-month profit per share level demonstrates the growth dynamics of ALX Oncology (ALXO), which rely on the readiness of research centers and production capacity reserves. This parameter reaches -0.88, correlating with the potential for global market reach driven by patents. Meanwhile, the safety of CD47 inhibitors in gastric cancer therapy without blood toxicity remains the key success factor.
Summary analytical data breakdowns for ALX Oncology Holdings Inc. (ALXO)

Fundamental analysis of EPS TTM allows for risk minimization by assessing the real return of each share. For ALX Oncology Holdings (ALXO), which develops unique oncology blockers, this metric reflects the efficiency of capitalizing on future pricing power. The calculation of this metric excludes the influence of capital structure, making the company's trailing twelve-month earnings per share an accurate indicator of operational resilience. This chart demonstrates the business's adaptation to cost inflation, which determines the fair value of the assets.